Scleroderma (Systemic Sclerosis) – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension, interstitial lung disease, and renal crisis in SSc patients underlie a high mortality rate. The treatment landscape for SSc is dominated by generics and off-label drugs to treat the wide array of SSc symptoms, with only Boehringer Ingelheim’s Ofev and Roche / Genentech’s Actemra as FDA-approved therapies. This report offers insights from real-world U.S. claims data into prescribing trends in SSc to help emerging players better understand current treatment practices in SSc and how to capitalize on the unmet needs in this underserved population.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
- How have Ofev and Actemra been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SSc patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Key drugs covered: Ofev, Actemra, select other biologics (e.g., rituximab)
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Table of contents
Rafael Widjajahakim, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. Prior to joining the company, he was a clinical research coordinator at University of Massachusetts Medical School. He received his master of science degree in clinical investigation from Boston University and his bachelor of science degree in biology from Suffolk University.